Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU
[NH]
New Drugs Online Report for catridecacog
Page accessed July 2, 2015) is a class of
recombinant Recombinant may refer to:
* Recombinant organism – an organism that contains a different combination of alleles from either of its parents.
* Recombinant DNA – a form of artificial DNA sequence
* Recombinant protein - artificially produced (and ...
factor XIII
Factor XIII or fibrin stabilizing factor is a zymogen found in blood of humans and some other animals. It is activated by thrombin to factor XIIIa. Factor XIIIa is an enzyme of the blood coagulation system that crosslinks fibrin. Deficiency of ...
A-subunit based
biopharmaceutical
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...
medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of
Factor XIII deficiency
Factor XIII deficiency occurs exceedingly rarely, causing a severe bleeding tendency. The incidence is one in a million to one in five million people, with higher incidence in areas with consanguineous marriage such as Iran that has the highest gl ...
. The medication prevents bleeding in patients with this condition, and has been approved by the U.S.
Food and Drug Administration
The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...
(FDA) for this use in the US in 2014.
Catridecacog: First drug to treat rare genetic blood clotting disorder
''The Pharmacist'' February 01, 2014
It was brought to market by Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder ...
.[
]
References
*
*
External links
*
Antihemorrhagics
Biopharmaceuticals
Orphan drugs
{{blood-drug-stub